Effect of Endostar combined with chemotherapy in advanced well-differentiated pancreatic neuroendocrine tumors

被引：10

作者：

Cheng, Yue-Juan ^{[1
]}

Meng, Chang-Ting ^{[1
]}

Ying, Hong-Yan ^{[1
]}

Zhou, Jian-Feng ^{[1
]}

Yan, Xiao-Yan ^{[2
]}

Gao, Xin ^{[3
]}

Zhou, Na ^{[1
]}

Bai, Chun-Mei ^{[1
]}

机构：

[1] Peking Union Med Coll Hosp, Dept Med Oncol, 1 Shuaifuyuan, Beijing 100730, Peoples R China

[2] Peking Univ, Clin Res Inst, Dept Biostat, Beijing, Peoples R China

[3] Peking Union Med Coll Hosp, Dept Radiol, Beijing, Peoples R China

来源：

MEDICINE | 2018年 / 97卷 / 45期

关键词：

dacarbazine; endostar; 5-fluorouracil; pancreatic neuroendocrine tumors; survival; temozolomide; PHASE-II TRIAL; TEMOZOLOMIDE; EFFICACY; STREPTOZOCIN; 5-FLUOROURACIL; FLUOROURACIL; MULTICENTER; BEVACIZUMAB; DACARBAZINE; SAFETY;

D O I：

10.1097/MD.0000000000012750

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The aim of the present study was to assess the effect of Endostar and temozolomide or dacarbazine plus 5-fluorouracil (5-FU) in patients with advanced pancreatic neuroendocrine tumors (pNETs). Phase II study of 14 patients with locally advanced or metastatic well-differentiated pNETs treated between April 2013 and September 2016. Patients received temozolomide or dacarbazine plus 5-FU, and Endostar. The primary outcome was the radiographic response rate. All 14 patients had nonfunctional pNETs. Six patients received temozolomide and 8 received dacarbazine + 5-FU, combined with Endostar. Thirteen patients were assessable for treatment response: 1(7%) with complete response, 5 (39%) with partial response, 5 (39%) with stable disease, and 2 (15%) with progression. The median progression-free survival was 12 months. The most common grade 1/2 toxicities were neutropenia (43%) and leucopenia (21%). Endostar combined with temozolomide or dacarbazine + 5-FU was effective in the treatment of advanced pNETs. The combinations were well tolerated.

引用

页数：5

共 50 条

[41] Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience [J].

Fine, Robert L. ;

Gulati, Anthony P. ;

Krantz, Benjamin A. ;

Moss, Rebecca A. ;

Schreibman, Stephen ;

Tsushima, Dawn A. ;

Mowatt, Kelley B. ;

Dinnen, Richard D. ;

Mao, Yuehua ;

Stevens, Peter D. ;

Schrope, Beth ;

Allendorf, John ;

Lee, James A. ;

Sherman, William H. ;

Chabot, John A. .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (03) :663-670

[42] Treatment Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors [J].

Liu, Alex J. ;

Ueberroth, Benjamin E. ;

McGarrah, Patrick W. ;

Buckner Petty, Skye A. ;

Kendi, Ayse Tuba ;

Starr, Jason ;

Hobday, Timothy J. ;

Halfdanarson, Thorvardur R. ;

Sonbol, Mohamad Bassam .

ONCOLOGIST, 2021, 26 (05) :383-388

[43] Current Status and Perspectives of Targeted Therapy in Well-Differentiated Neuroendocrine Tumors [J].

Naraev, Boris G. ;

Strosberg, Jonathan R. ;

Halfdanarson, Thorvardur R. .

ONCOLOGY, 2012, 83 (03) :117-127

[44] Evaluation of the Combination 5-Fluorouracil, Dacarbazine, and Epirubicin in Patients With Advanced Well-Differentiated Neuroendocrine Tumors [J].

Walter, Thomas ;

Bruneton, Domitille ;

Cassier, Philippe A. ;

Hervieu, Valerie ;

Pilleu, Frank ;

Scoazec, Jean Yves ;

Chayvialle, Jean Alain ;

Lombard-Bohas, Catherine .

CLINICAL COLORECTAL CANCER, 2010, 9 (04) :248-254

[45] Multi-center clinical evaluation of streptozocin-based chemotherapy for advanced pancreatic neuroendocrine tumors in Japan: focus on weekly regimens and monotherapy [J].

Shibuya, Hitoshi ;

Hijioka, Susumu ;

Sakamoto, Yasunari ;

Ito, Tetsuhide ;

Ueda, Keijiro ;

Komoto, Izumi ;

Kobayashi, Noritoshi ;

Kudo, Atsushi ;

Yasuda, Hiroaki ;

Miyake, Hayato ;

Arita, Junichi ;

Kiritani, Sho ;

Ikeda, Masafumi ;

Imaoka, Hiroshi ;

Ueno, Makoto ;

Kobayashi, Satoshi ;

Furuta, Mitsuhiro ;

Nagashio, Yoshikuni ;

Murohisa, Gou ;

Aoki, Taku ;

Matsumoto, Shigemi ;

Motoya, Masayo ;

Azemoto, Nobuaki ;

Itakura, Jun ;

Horiguchi, Shigeru ;

Yogi, Tatsuji ;

Kawagoe, Tetsuro ;

Miyaoka, Youichi ;

Imamura, Fumito ;

Senju, Michio ;

Arioka, Hitoshi ;

Hara, Kazuo ;

Imamura, Masayuki ;

Okusaka, Takuji .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (04) :661-668

[46] Ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors (RamuNET): study protocol for a multicenter single-arm trial [J].

Krug, Sebastian ;

Kegel, Thomas ;

Gress, Thomas M. ;

Rinke, Anja ;

Apostolidis, Leonidas ;

Jann, Henning ;

Koenig, Alexander ;

Hoersch, Dieter ;

Schrader, Joerg ;

Ettrich, Thomas J. ;

Richter, Michael ;

Steighardt, Joerg ;

Michl, Patrick .

BMC CANCER, 2021, 21 (01)

[47] Meta-Analysis of Prognostic Factors for Recurrence of Resected Well-Differentiated Pancreatic Neuroendocrine Tumors [J].

Li, Yuanliang ;

Fan, Guohui ;

Yu, Fuhuan ;

Tian, Chao ;

Tan, Huangying .

NEUROENDOCRINOLOGY, 2021, 111 (12) :1231-1237

[48] Epigenetic-based targeted therapies for well-differentiated pancreatic neuroendocrine tumors: recent advances and future perspectives [J].

Marini, Francesca ;

Giusti, Francesca ;

Brandi, Maria Luisa .

EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2021, 16 (06) :295-307

[49] Pattern of disease recurrence and treatment after surgery for nonfunctioning well-differentiated pancreatic neuroendocrine tumors [J].

Partelli, Stefano ;

Landoni, Luca ;

Andreasi, Valentina ;

Nessi, Chiara ;

Muffatti, Francesca ;

Crippa, Stefano ;

Cingarlini, Sara ;

Bassi, Claudio ;

Falconi, Massimo .

SURGERY, 2020, 168 (05) :816-824

[50] Oncogenic pathway signatures predict the risk of progression and recurrence in well-differentiated pancreatic neuroendocrine tumors [J].

Mederos, Michael A. ;

Court, Colin M. ;

Dipardo, Benjamin J. ;

Pisegna, Joseph R. ;

Dawson, David W. ;

Hines, O. Joe ;

Donahue, Timothy R. ;

Graeber, Thomas G. ;

Girgis, Mark D. ;

Tomlinson, James S. .

JOURNAL OF SURGICAL ONCOLOGY, 2024, 130 (05) :1070-1077

← 1 2 3 4 5 →